Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

Open access

Abstract

One-third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and MEK inhibition progress within 6 months. Treatment options for these patients remain limited. Here we analyse 20 BRAF(V600)-mutant melanoma metastases derived from 10 patients treated with the combination of dabrafenib and trametinib for resistance mechanisms and genetic correlates of response. Resistance mechanisms are identified in 9/11 progressing tumours and MAPK reactivation occurred in 9/10 tumours, commonly via BRAF amplification and mutations activating NRAS and MEK2. Our data confirming that MEK2(C125S), but not the synonymous MEK1(C121S) protein, confers resistance to combination therapy highlight the functional differences between these kinases and the preponderance of MEK2 mutations in combination therapy-resistant melanomas. Exome sequencing did not identify additional progression-specific resistance candidates. Nevertheless, most melanomas carried additional oncogenic mutations at baseline (for example, RAC1 and AKT3) that activate the MAPK and PI3K pathways and are thus predicted to diminish response to MAPK inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms6694

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

See all 380

Metadata

Authors
Long, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., Howle, J., Hayward, N. K., Johansson, P., Scolyer, R. A., Kefford, R. F., & Rizos, H.
Affiliations
  • The University of Sydney (AU)
  • Royal Prince Alfred Hospital (AU)
  • QIMR Berghofer Medical Research Institute (AU)
Corresponding author
Rizos, Helen
Venue
Nature Communications
Published
2014-12-02
Volume
5
Issue
1
Pages
5694-5694
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2003402062
Cited by
375
References
62
Citations by year
2026: 16 · 2025: 21 · 2024: 27 · 2023: 44 · 2022: 26 · 2021: 35 · 2020: 36 · 2019: 33 · 2018: 33 · 2017: 43 · 2016: 34 · 2015: 24 · 2014: 1
FWCI
13.92
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • Westmead Millennium Institute for Medical Research
  • Australian Cancer Research Foundation
  • Cancer Institute NSW
  • Melanoma Institute Australia
  • Medical Research Council
  • National Health and Medical Research Council (633004)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
dabrafenib, trametinib, combination therapy resistance, MAPK pathway reactivation, BRAF amplification, NRAS mutation, PI3K signaling, Rac1, AKT3, BRAF V600E mutation, resistance mechanisms
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Humans, Imidazoles, Melanoma, Membrane Proteins, Oximes, Pyridones, Pyrimidinones, Skin Neoplasms, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, GTP Phosphohydrolases, rac1 GTP-Binding Protein, MAP Kinase Kinase 1, MAP Kinase Kinase 2, Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins c-akt

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. https://app.cochat.ai/papers/10.1038/ncomms6694
The paper
Long, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., Howle, J., Hayward, N. K., Johansson, P., Scolyer, R. A., Kefford, R. F., & Rizos, H. (2014). Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nature Communications. https://doi.org/10.1038/ncomms6694

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.